---
title: "Chloroquine–resin complexes: formulation, biopharmaceutics, and antimalarial evaluation"
id: "pubmed-42556438"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42556438"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42556438/"
doi: "10.1016/j.ijpharm.2026.127272"
published_at: "2026-09-05T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Chloroquine–resin complexes: formulation, biopharmaceutics, and antimalarial evaluation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42556438
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42556438/)
- **DOI:** [10.1016/j.ijpharm.2026.127272](https://doi.org/10.1016%2Fj.ijpharm.2026.127272)
- **Published At:** 2026-09-05T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Malaria remains a significant global health problem, particularly in children under five, and pediatric dosing often requires tablet fragmentation that increases bitterness and may reduce adherence. - The study tested whether a **chloroquine-resin complex (CLQ-R)** could mask bitterness while preserving chloroquine's pharmacokinetic profile and antimalarial efficacy. - CLQ-R was prepared at a 1:1 (w/w) drug-to-resin ratio using **polacrilin potassium (Amberlite IRP88)** as the ion-exchange resin for taste masking. - In vitro antimalarial activity was evaluated against **Plasmodium falciparum 3D7** with parasite proliferation measured by **SYBR Green** DNA staining. - Pharmacokinetic (plasma concentration) and biochemical parameters were measured after oral administration of CLQ or CLQ-R in mice. - In vivo efficacy was assessed using **Plasmodium berghei ANKA** infection in C57BL/6 mice with the four-day suppressive test and recrudescence test; parasitemia was quantified by flow cytometry. - Taste perception was measured using a 48-hour two-bottle preference test to assess palatability. - The abstract reports that **CLQ-R displayed similar plasma concentration and biochemical profiles to CLQ**, indicating preserved pharmacokinetics and no reported biochemical differences in the parameters measured. - The source text is truncated and does not report the remainder of the results, including detailed in vitro efficacy outcomes, in vivo antimalarial performance, statistical data, or specific taste-preference results; those details were not reported in the available source.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42556438/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42556438%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42556438/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42556438/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42556438/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42556438/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42556438/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42556438/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42556438%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42556438%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42556438/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42556438/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42556438/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42556438/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0378-5173\(26\)00720-9 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42556438/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42556438/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42556438/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42556438/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42556438/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42556438/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42556438/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42556438/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42556438/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42556438/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42556438/) . 2026 Sep 5:702:127272. doi: 10.1016/j.ijpharm.2026.127272. Epub 2026 Aug 5. # Comprehensive evaluation of chloroquine-resin complexes: functional, biopharmaceutical and antimalarial performance [Tatiana A Pádua](https://pubmed.ncbi.nlm.nih.gov/?term=P%C3%A1dua+TA&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Mariana X V Passos](https://pubmed.ncbi.nlm.nih.gov/?term=Passos+MXV&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Ellen D Mascarenhas](https://pubmed.ncbi.nlm.nih.gov/?term=Mascarenhas+ED&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Thadeu Estevam M M Costa](https://pubmed.ncbi.nlm.nih.gov/?term=Costa+TEMM&cauthor_id=42556438)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-2 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.; Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Gabriel P E Silveira](https://pubmed.ncbi.nlm.nih.gov/?term=Silveira+GPE&cauthor_id=42556438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-3 "Serviço de Equivalência e Farmacocinética, Vice-presidência de Produção e Inovação da Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Douglas P Pinto](https://pubmed.ncbi.nlm.nih.gov/?term=Pinto+DP&cauthor_id=42556438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-3 "Serviço de Equivalência e Farmacocinética, Vice-presidência de Produção e Inovação da Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Ramayana M M Brito](https://pubmed.ncbi.nlm.nih.gov/?term=Brito+RMM&cauthor_id=42556438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-4 "Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Canberra, ACT, Australia."), [Alexander G Maier](https://pubmed.ncbi.nlm.nih.gov/?term=Maier+AG&cauthor_id=42556438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-4 "Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Canberra, ACT, Australia."), [Lilian L Bueno](https://pubmed.ncbi.nlm.nih.gov/?term=Bueno+LL&cauthor_id=42556438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-5 "Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil."), [Eduardo G R de Sousa](https://pubmed.ncbi.nlm.nih.gov/?term=de+Sousa+EGR&cauthor_id=42556438)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-6 "Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Elaine C Rosas](https://pubmed.ncbi.nlm.nih.gov/?term=Rosas+EC&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Thiago F Guimarães](https://pubmed.ncbi.nlm.nih.gov/?term=Guimar%C3%A3es+TF&cauthor_id=42556438)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#full-view-affiliation-7 "Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.. Electronic address: thiago.frances@fiocruz.br.") Affiliations Expand ### Affiliations * 1 Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 2 Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.; Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 3 Serviço de Equivalência e Farmacocinética, Vice-presidência de Produção e Inovação da Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 4 Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Canberra, ACT, Australia. * 5 Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. * 6 Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 7 Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.. Electronic address: thiago.frances@fiocruz.br. * PMID: **42556438** * DOI: [ 10.1016/j.ijpharm.2026.127272 ](https://doi.org/10.1016/j.ijpharm.2026.127272) Item in Clipboard # Comprehensive evaluation of chloroquine-resin complexes: functional, biopharmaceutical and antimalarial performance Tatiana A Pádua et al. Int J Pharm. 2026. Show details Display options Display options Format Abstract PubMed PMID Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42556438/) . 2026 Sep 5:702:127272. doi: 10.1016/j.ijpharm.2026.127272. Epub 2026 Aug 5. ### Authors [Tatiana A Pádua](https://pubmed.ncbi.nlm.nih.gov/?term=P%C3%A1dua+TA&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Mariana X V Passos](https://pubmed.ncbi.nlm.nih.gov/?term=Passos+MXV&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Ellen D Mascarenhas](https://pubmed.ncbi.nlm.nih.gov/?term=Mascarenhas+ED&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Thadeu Estevam M M Costa](https://pubmed.ncbi.nlm.nih.gov/?term=Costa+TEMM&cauthor_id=42556438)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-2 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.; Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Gabriel P E Silveira](https://pubmed.ncbi.nlm.nih.gov/?term=Silveira+GPE&cauthor_id=42556438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-3 "Serviço de Equivalência e Farmacocinética, Vice-presidência de Produção e Inovação da Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Douglas P Pinto](https://pubmed.ncbi.nlm.nih.gov/?term=Pinto+DP&cauthor_id=42556438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-3 "Serviço de Equivalência e Farmacocinética, Vice-presidência de Produção e Inovação da Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Ramayana M M Brito](https://pubmed.ncbi.nlm.nih.gov/?term=Brito+RMM&cauthor_id=42556438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-4 "Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Canberra, ACT, Australia."), [Alexander G Maier](https://pubmed.ncbi.nlm.nih.gov/?term=Maier+AG&cauthor_id=42556438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-4 "Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Canberra, ACT, Australia."), [Lilian L Bueno](https://pubmed.ncbi.nlm.nih.gov/?term=Bueno+LL&cauthor_id=42556438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-5 "Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil."), [Eduardo G R de Sousa](https://pubmed.ncbi.nlm.nih.gov/?term=de+Sousa+EGR&cauthor_id=42556438)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-6 "Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Elaine C Rosas](https://pubmed.ncbi.nlm.nih.gov/?term=Rosas+EC&cauthor_id=42556438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-1 "Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil."), [Thiago F Guimarães](https://pubmed.ncbi.nlm.nih.gov/?term=Guimar%C3%A3es+TF&cauthor_id=42556438)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42556438/#short-view-affiliation-7 "Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos \(Farmanguinhos\), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.. Electronic address: thiago.frances@fiocruz.br.") ### Affiliations * 1 Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 2 Laboratório de Farmacologia Aplicada, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.; Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 3 Serviço de Equivalência e Farmacocinética, Vice-presidência de Produção e Inovação da Saúde, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 4 Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Canberra, ACT, Australia. * 5 Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. * 6 Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil. * 7 Seção de Análise e Identificação de Compostos com Potencial Terapêutico, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.. Electronic address: thiago.frances@fiocruz.br. * PMID: **42556438** * DOI: [ 10.1016/j.ijpharm.2026.127272 ](https://doi.org/10.1016/j.ijpharm.2026.127272) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Malaria remains a major global health burden, especially in children under the age of five. Pediatric treatment often requires tablet fragmentation for its dose adjustment according to body weight, which intensifies bitterness and may reduce treatment adherence. Complexation of bitter-tasting drugs with ion-exchange resins for taste masking is a promising strategy to improve palatability. Here, we evaluated whether a chloroquine-resin complex (CLQ-R) preserves the pharmacokinetic profile and antimalarial efficacy of chloroquine diphosphate (CLQ) while masking its bitter taste. CLQ-R was prepared at a 1:1 (w/w) drug-to-resin ratio using polacrilin potassium (Amberlite IRP88). The in vitro antimalarial activity of CLQ-R was assessed using Plasmodium falciparum 3D7 strain, and the parasite proliferation was determined by SYBR Green DNA-staining. CLQ plasma concentrations and mice biochemical parameters were evaluated following oral administration of CLQ or CLQ-R. The in vivo antimalarial activity was evaluated in P. berghei ANKA-infected C57BL/6 mice using the four-day suppressive and recrudescence tests, with parasitemia assessed by flow cytometry. Taste perception was determined by 48-hour two-bottle preference test. CLQ-R displayed similar plasma concentration and biochemical profiles to CLQ. CLQ-R was ab
## Related Clinical Research

- [Widening medication adherence gap: impact on modern therapeutics and system solutions](https://medichelpline.com/clinical-feed/plos-medicine-0-the-widening-medication-adherence-gap.md)
- [AA147 and Metabolically Activated Proteostasis Regulators Suppress CD4+ TH17 Differentiation](https://medichelpline.com/clinical-feed/biorxiv-0-metabolically-activated-proteostasis-regulators-reduce-differentiation-of-cd4.md)
- [Microspheres for Myocardial Infarction Therapy: Design, Delivery, and Applications](https://medichelpline.com/clinical-feed/pubmed-42542259.md) (DOI: 10.1016/j.ijpharm.2026.127262)
- [Liposuction versus conservative therapy for lipoedema: multicentre randomised trial in Germany](https://medichelpline.com/clinical-feed/pubmed-42692034.md) (DOI: 10.1016/S0140-6736(26)00910-4)
- [MEL-Steered PharmacoNet: Adapting DL Prescreening to Synthon-Based Docking for Target-Specific Vir](https://medichelpline.com/clinical-feed/biorxiv-0-when-dl-based-prescreening-meets-synthon-based-docking-target-adapting.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.